Gulf Lab & Testing Demand 2026: Pharma Localization Rises

Global South EXPOHUB AI Analytics · 2026-10-15

Gulf governments are moving pharmaceuticals, chemicals and other regulated industries onshore, and every new plant brings a parallel requirement: accredited laboratories that can test, release and certify what it produces. Context: Industrial Strategy Turns Quality Infrastructure Into a Growth Driver The UAE’s Operation 300bn strategy aims to lift the industrial sector’s contribution to GDP from AED 133 billion to AED 300 billion by 2031 (UAE Government portal). Pharmaceuticals sit among its eleven priority sectors, alongside petrochemicals, food and beverage, hydrogen and medical technology. In February 2026 the UAE launched the Emirates Drug Establishment, a regulator whose national manufacturing project combines regulation, manufacturing, oversight and quality control in one system. Saudi Arabia pursues the same direction under Vision 2030: according to the Saudi Press Agency, the Kingdom’s import reliance for medicines fell from 80% in 2019 to 70% in 2023. Key Numbers AED 133 billion to AED 300 billion: the UAE’s target for industrial GDP contribution by 2031 (Operation 300bn) 37 facilities licensed by the Emirates Drug Establishment to produce human pharmaceutical and medical products (February 2026) USD 1.76 billion: estimated 2025 size of the UAE testing, inspection and certification market, forecast at USD 2.34 billion by 2030, a 5.78% CAGR (Mordor Intelligence) USD 25.5 billion in 2025 to a forecast USD 49.6 billion in 2034: GCC pharmaceutical market; IMARC Group projects a 7.45% CAGR for 2026-2034 80% to 70%: Saudi Arabia’s import reliance for medicines, 2019 to 2023 (Saudi Press Agency) 200+ priority products identified for Saudi localization since 2020, about 40% of the government’s annual health procurement of USD 3.7 billion (Saudi Press Agency) Deep Dive: Why Localization Is Also a Laboratory Story Producing a medicine locally is only half of the task; the other half is proving that each batch meets specification. Raw materials, intermediates and finished products all require analytical testing under recognized quality systems. Policy in both countries reflects this pairing. The Emirates Drug Establishment integrates quality control into its manufacturing project, and in May 2026 it signed agreements and memoranda with industry and academic partners, including the Abu Dhabi Quality and Conformity Council, and held a workshop for quality heads at national factories on Good Manufacturing Practice, quality systems and harmonised inspection procedures. Saudi Arabia shows the same pattern at project level. Partnerships to localize up to seven insulin products, targeting over 80% of domestic insulin demand by 2027, and the Kingdom’s first fully developed biosimilar (enoxaparin) all rely on validated analytical methods and release testing. The SPA also lists, among the Kingdom’s initiatives, the GCC’s only API facility adhering to GMP standards, a type of site where analytical capability decides whether production can scale. Beyond the national level, the GCC Standardization Organization (GSO) maintains a catalogue of more than 25,000 adopted standards (ANSI, 2020), and says at least 80% of them are international standards. A single GSO standard becomes the national standard in all member states, which creates a harmonized technical baseline across the region and supports demand for accredited testing capacity. Pharmaceuticals are not the only driver. Mordor Intelligence attributes the UAE testing market’s growth to product-safety regulation, diversification into pharmaceuticals, hydrogen and advanced manufacturing, and rising trade volumes. Accreditation also appears to build capability: a December 2025 Scientific Reports study by Alomair et al., researchers at the Saudi Accreditation Center (SAAC), compared 44 Saudi laboratories accredited under ISO/IEC 17025:2017 at their initial assessment and first surveillance assessment, and found nonconformities fell by about 41% in testing laboratories and 46% in calibration laboratories. The sample is small and the authors are affiliated with the accreditation body, but the direction points to a maturing quality ecosystem. What This Means for Business For laboratory equipment and consumables suppliers: new plants, regulators and accreditation programs create recurring demand for analytical instruments, automation and monitoring. For testing and certification providers: localization widens the range of regulated products needing pre-market testing, calibration and assurance within the region. For manufacturers and investors: qualified quality-control capacity and trained analysts can shorten the path from construction to commercial release. Frequently Asked Questions What is the UAE’s Operation 300bn? The national industrial strategy aims to raise industry’s GDP contribution from AED 133 billion to AED 300 billion by 2031, with pharmaceuticals, chemicals, hydrogen and medical technology among its priority sectors. How fast is Saudi Arabia localizing medicines? Import reliance fell from 80% in 2019 to 70% in 2023, and more than 200 priority products have been identified for local production since 2020, about 40% of government health procurement (Saudi Press Agency). Why does pharmaceutical localization increase demand for laboratories? Each locally produced medicine needs testing of materials and finished batches under recognized quality systems, which adds demand for instruments, accredited testing and quality staff. How large is the GCC pharmaceutical market? IMARC Group estimates it at USD 25.5 billion in 2025 and forecasts USD 49.6 billion by 2034, with a 7.45% CAGR projected for 2026-2034. Related Content For more on industrial strategy and market access across the Global South, see our related briefs on trade and infrastructure cooperation.

Context event: ArabLab+

Pharmaceuticals, Biotechnology & Life Sciences · United Arab Emirates · BRICS